TY - JOUR T1 - Runners with mid-portion Achilles tendinopathy have greater triceps surae intracortical inhibition than healthy controls JF - medRxiv DO - 10.1101/2021.06.25.21259561 SP - 2021.06.25.21259561 AU - Gabriel L. Fernandes AU - Lucas B. R. Orssatto AU - Anthony J. Shield AU - Gabriel S. Trajano Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/11/2021.06.25.21259561.abstract N2 - Objectives This study aimed to investigate short-interval intracortical inhibition (SICI) and muscle function in the Triceps surae of runners with mid-portion Achilles tendinopathy (AT).Methods Runners with (n=11) and without (n=13) AT were recruited. Plantar flexor isometric peak torque and rate of torque development (RTD) were measured using an isokinetic dynamometer. Triceps surae endurance was measured as single leg heel raise (SLHR) to failure test. SICI was assessed using paired-pulse transcranial magnetic stimulation during a sustained contraction at 10% of plantar flexor isometric peak torque.Results Triceps surae SICI was 14.3% (95%CI: -2.1 to 26.4) higher in AT than control group (57.9%, 95%CI: 36.2, to 79.6; and 43.6% 95%CI:16.2 to 71.1; p=0.032) irrespective of the tested muscle. AT performed 16 (95%CI: 7.9 to 23.3, p<0.001) fewer SLHR repetitions on the symptomatic side compared to controls, and 14 (95%CI: 5.8 to 22.0, p=0.004), fewer SLHR repetitions on the non-symptomatic compared to controls. We found no between-groups differences in isometric peak torque (p=0.971) or RTD (p=0.815).Perspective Our data suggest greater intracortical inhibition for the Triceps surae muscles for the AT group accompanied by reduced SLHR endurance, without deficits in isometric peak torque or RTD. The increased SICI observed in the AT group could be negatively influencing Triceps surae endurance; thus, rehabilitation aiming to reduce intracortical inhibition should be considered to improve patient outcomes. Furthermore, SLHR is a useful clinical tool to assess plantar flexor function in AT patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Queensland University of Technology Human Research and Ethics Committee in line with the Declaration of Helsinki. Data collection was conducted during the COVID-19 pandemic and all safety procedures followed local state government policies. QUT ethics approval number - 1600001056I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData material will be send as requested ER -